ADU 214

Drug Profile

ADU 214

Alternative Names: ADU-214; JNJ-64041757

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aduro BioTech
  • Developer Aduro BioTech; Janssen
  • Class Antineoplastics; Gene therapies; Immunotherapies
  • Mechanism of Action Epidermal growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Non-small cell lung cancer
  • Preclinical Ovarian cancer

Most Recent Events

  • 17 Oct 2017 Interim efficacy and adverse events data from a phase I trial in Non-small cell lung cancer released by Aduro Biotech
  • 17 Oct 2017 Janssen plans a clinical trial for Non-small cell lung cancer (Combination therapy)
  • 29 Dec 2016 Janssen reinitiates enrolment in a phase I trial in Non-small cell lung cancer in USA (IV) (NCT02592967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top